Sometimes good news for your competitor turns out to be even better news for you. That's exactly what happened Tuesday when Olema Pharmaceuticals (OLMA) soared more than 150% after Roche Holdings (RHHBY) announced successful trial results for a rival breast cancer drug.

Olema's stock exploded on session volume of 45.12 million shares, compared to its typical average of 1.171 million. The catalyst? Roche proved that the entire drug category actually works in a massive new market.

Roche's Breakthrough Trial Results

Roche announced Phase 3 results from its lidERA Breast Cancer study, which tested giredestrant as an adjuvant endocrine treatment for estrogen receptor-positive, HER2-negative early-stage breast cancer. Adjuvant treatments are those given after the main treatment to prevent cancer from returning.

The trial met its primary endpoint at a pre-planned interim analysis, showing a statistically significant and clinically meaningful improvement in invasive disease-free survival compared to standard-of-care endocrine therapy. Even better, giredestrant was well tolerated with no unexpected safety concerns, and the adverse events aligned with its known safety profile.

While overall survival data weren't yet mature at the time of interim analysis, researchers observed a clear positive trend. Roche plans to present the full data at an upcoming medical meeting.

This marks the first Phase 3 trial of a selective estrogen receptor degrader (SERD) to demonstrate significant benefit in the adjuvant setting. That's a big deal because the majority of breast cancer cases are diagnosed at an early stage, making this a substantial market opportunity.

The lidERA results represent the second positive Phase 3 readout for giredestrant, following the evERA Breast Cancer trial presented at the European Society for Medical Oncology Congress 2025.

Why Olema Benefits From Roche's Success

Here's where it gets interesting for Olema investors. An Oppenheimer analyst noted that this is the first trial ever to show a clinical benefit head-to-head against an aromatase inhibitor, the current standard treatment.

"We were not expecting this readout as the entire narrative has been around Roche's evERA and persevERA trials. Nonetheless, the data are a welcome surprise. Early breast cancer is a multi-billion dollar market, and one we did not have in our model," Oppenheimer wrote.

The successful results also reduce risk for Roche's persevERA Phase 3 trial, which is testing oral SERDS against aromatase inhibitors in the frontline metastatic setting.

Olema's lead drug candidate, palazestrant, is a proprietary, orally available complete estrogen receptor antagonist and SERD. The company currently has palazestrant in two Phase 3 clinical trials.

Olema recently initiated the OPERA-02 Phase 3 trial testing palazestrant in combination with ribociclib for frontline ER-positive/HER2-negative metastatic breast cancer. The company continues enrolling patients in the OPERA-01 Phase 3 trial of palazestrant as a monotherapy in second- and third-line ER-positive/HER2-negative metastatic breast cancer.

Roche's successful results essentially validate Olema's entire approach. If giredestrant works in early breast cancer, palazestrant has a much clearer path to success in its own trials. That's why Oppenheimer increased the estimated probability of success for palazestrant and raised its price forecast from $22 to $45.

Price Action: Olema Pharmaceuticals shares were up 166.65% at $22.71, while Roche Holding shares climbed 8.33% to $48.29 at the time of publication on Tuesday.